E7386 Enhances Lenvatinib’s Antitumor Activity in Preclinical Models and Human Hepatocellular Carcinoma

Agavni Mesropian; Albert Gris‐Oliver; Ugne Balaseviciute; Alka A. Potdar; Takayuki Kimura; Jialing Shen; Martí Torres-Marcén; Jordi Abril‐Fornaguera; Marta Piqué‐Gili; D. Camell-Raventós; Judit Peix; Elisa Fernández-Martínez; Júlia Huguet‐Pradell; Ana Hernández de Sande; Ieva Keraite; Roger Esteban-Fabró; Marina Bárcena‐Varela; Katherine E. Lindblad; Amaia Lujambio; Ernesto Guccione; Swan N. Thung; Masafumi Ikeda; Masatoshi Kudo; Daniela Sia; Roser Pinyol; Josep M. Llovet

doi:10.1158/1078-0432.ccr-25-0725

Article2025

Data from E7386 Enhances Lenvatinib’s Antitumor Activity in Preclinical Models and Human Hepatocellular Carcinoma

Agavni Mesropian, Albert Gris‐Oliver, Ugne Balaseviciute, Alka A. Potdar, Takayuki Kimura, Jialing Shen, Martí Torres-Marcén, Jordi Abril‐Fornaguera, Marta Piqué‐Gili, D. Camell-Raventós, Judit Peix, Elisa Fernández-Martínez, Júlia Huguet‐Pradell, Ana Hernández de Sande, Ieva Keraite, Roger Esteban-Fabró, Marina Bárcena‐Varela, Katherine E. Lindblad, Amaia Lujambio, Ernesto Guccione, Swan N. Thung, Masafumi Ikeda, Masatoshi Kudo, Daniela Sia, Roser Pinyol, Josep M. Llovet

Article2023

A phase 1b study of E7386, a CREB-binding protein (CBP)/β-catenin interaction inhibitor, in combination with lenvatinib in patients with advanced hepatocellular carcinoma.

Masafumi Ikeda, Naoya Kato, Shunsuke Kondo, Yoshitaka Inaba, Kazuomi Ueshima, Mitsuhito Sasaki, Hiroaki Kanzaki, Hiroshi Ida, Hiroshi Imaoka, Yasunori Minami, Shuichi Mitsunaga, Naoshi Nishida, Sadahisa Ogasawara, Kazuo Watanabe, Takatoshi Sahara, Nozomi Hayata, Shintaro Yamamuro, Takayuki Kimura, Toshiyuki Tamai, Masatoshi Kudo

Article2025

Supplementary Data 1 from E7386 Enhances Lenvatinib’s Antitumor Activity in Preclinical Models and Human Hepatocellular Carcinoma

Agavni Mesropian, Albert Gris‐Oliver, Ugne Balaseviciute, Alka A. Potdar, Takayuki Kimura, Jialing Shen, Martí Torres-Marcén, Jordi Abril‐Fornaguera, Marta Piqué‐Gili, D. Camell-Raventós, Judit Peix, Elisa Fernández-Martínez, Júlia Huguet‐Pradell, Ana Hernández de Sande, Ieva Keraite, Roger Esteban-Fabró, Marina Bárcena‐Varela, Katherine E. Lindblad, Amaia Lujambio, Ernesto Guccione, Swan N. Thung, Masafumi Ikeda, Masatoshi Kudo,

Article2018

Long‐term antitumor effect of lenvatinib on unresectable hepatocellular carcinoma with portal vein invasion

Haruhiko Takeda, Norihiro Nishijima, Akihiro Nasu, Hideyuki Komekado, Ryuichi Kita, Tōru Kimura, Masatoshi Kudo, Yukio Osaki

Article2021

Immunomodulatory Effects of Lenvatinib Plus Anti–Programmed Cell Death Protein 1 in Mice and Rationale for Patient Enrichment in Hepatocellular Carcinoma

Laura Torrens, Carla Montironi, Marc Puigvehí, Agavni Mesropian, Jack Leslie, Philipp K. Haber, Miho Maeda, Ugne Balaseviciute, Catherine E. Willoughby, Jordi Abril‐Fornaguera, Marta Piqué‐Gili, Miguel Torres‐Martín, Judit Peix, Daniel Geh, Erik Ramón-Gil, Behnam Saberi, Scott L. Friedman, Derek A. Mann, Daniela Sia, Josep M. Llovet

Hepatology

E7386 Enhances Lenvatinib’s Antitumor Activity in Preclinical Models and Human Hepatocellular Carcinoma

Abstract

Discussion(0)

Related publications

Data from E7386 Enhances Lenvatinib’s Antitumor Activity in Preclinical Models and Human Hepatocellular Carcinoma

A phase 1b study of E7386, a CREB-binding protein (CBP)/β-catenin interaction inhibitor, in combination with lenvatinib in patients with advanced hepatocellular carcinoma.

Supplementary Data 1 from E7386 Enhances Lenvatinib’s Antitumor Activity in Preclinical Models and Human Hepatocellular Carcinoma

Long‐term antitumor effect of lenvatinib on unresectable hepatocellular carcinoma with portal vein invasion

Immunomodulatory Effects of Lenvatinib Plus Anti–Programmed Cell Death Protein 1 in Mice and Rationale for Patient Enrichment in Hepatocellular Carcinoma